EGFR and non-small cell lung carcinoma: Combined analysis of overall survival (OS) data from two randomized phase III trials, LUX-Lung 3 and LUX-Lung 6, showed that overall survival was improved with the 2nd generation EGFR-TKI afatinib (31.7 months) over standard chemotherapy (20.7 months) for patients with Del-19 mutant NSCLC (p = 0.0001) [8].